MODELING THE VALUE OF INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE IN THE UNITED STATES
Author(s)
Moderator: Charles Makin, BSPharm, MS, MBA, MM, Biogen, Cambridge, MA, USA
Speakers: Dana P. Goldman, PhD, Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA; Peter I Neumann, ScD, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts University, Boston, MA, USA; Sue Peschin, MHS, Alliance for Aging Research, Washington, DC, USA
Presentation Documents
Traditional economic models that estimate direct medical cost offsets may underestimate the value of innovative therapies that have broader system level benefits. This symposium explores a broader approach to valuing innovative therapies, including potential innovative therapies in Alzheimer’s disease if approved, highlighting the potentially broader l impact on patients and caregivers, and the comprehensive healthcare system. Panelists will discuss the implications of the approach within the context of a broader value assessment framework and affordability.
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA